Repetitive Transcranial Stimulation (rTMS) for Resistant Depression in Adolescents
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01170520|
Recruitment Status : Unknown
Verified January 2012 by Shalvata Mental Health Center.
Recruitment status was: Recruiting
First Posted : July 27, 2010
Last Update Posted : January 5, 2012
The investigators hypothesis that repetitive transcranial Stimulation (rTMS) is a safe and effective add-on therapy for resistent depression in adolescent patients.
A group of adolescents suffering from non psychotic major depression that was resistant to at least 2 drug trials and a trail of psychotherapy will be recruited. After an informed consent procedure for both parents and patients, patients will go through a clinical and cognitive evaluation. They will receive a protocol of 4 weeks (20 work days) of rTMS using the figure of 8 magstim coil at 100% threshold, 42 trains of 4 seconds each, intertrain interval of 30 sec to the LDPC, 1680 pulses per day. Then they will be reevaluated.
|Condition or disease||Intervention/treatment||Phase|
|Adolescent Depression||Device: repetitive transcranial Stimulation||Phase 1 Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||24 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||The Addition of rTMS to the Therapy of Adolescents That Suffer From Treatment Resistant Depression: An Open Label Study|
|Study Start Date :||August 2010|
|Estimated Primary Completion Date :||September 2013|
Device: repetitive transcranial Stimulation
rTMS using the figure of 8 magstim for 4 weeks or 20 work days, using 100% threshold to the LDPFC 42 trains per day 4 sec pretrain inter train interval of 30 sec.
- Child Depression Rating Scale (CDRS) comparison before after therapy [ Time Frame: 4 weeks ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01170520
|Contact: Yuval Bloch, MDemail@example.com; firstname.lastname@example.org|
|Shalvata Mental health Center||Not yet recruiting|
|Hod Hasharon, Israel|
|Contact: Yuval Bloch, MD 972-97478644|
|Principal Investigator: Yuval Bloch, MD|
|Shalvata Mental Health Center||Recruiting|
|Hod Hasharon, Israel|
|Contact: Yuval Bloch, MD 972-9-7478510 email@example.com|